Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda to Discontinue Natpar/Natpara Production at End of 2024
October 5, 2022
- Sumitomo Rolls Out Hand Rehabilitation System in Japan as 1st Frontier Business Product
October 4, 2022
- Idorsia’s Insomnia Med Meets PIII Goal in Japan, Filing Planned for H1 2023
October 4, 2022
- Shionogi to End Sale of Aimix, Sumitomo to Continue
October 4, 2022
- Taiho Gets US Nod for Bile Duct Cancer Drug Futibatinib
October 4, 2022
- Sun Pharma Taps Haruko Yamabe as Japan Chief
October 4, 2022
- Novartis Homes in on 5 Therapy Areas and 4 Markets, Eyes Top 3 Multinational Rank in Japan: CEO
October 4, 2022
- Celltrion Aims to Market 11 Biosimilars in Japan, Infliximab “Biobetter” in the List
October 3, 2022
- Novartis Ordered to Pay US$177.8 Million to Daiichi Sankyo over Patent Row
October 3, 2022
- Rohto Begins PIIb Dry Eye Study for JAK Drug Delgocitinib in Japan
October 3, 2022
- EMA Accepts Astellas’ Hot Flash Drug for Review
October 3, 2022
- Sanofi Seeks Japan Nod for Once-Weekly Hemophilia Med
October 3, 2022
- Ferring Japan CEO Confident of Growth in Fertility Drugs Spurred by Rising Demand on Health Coverage
September 30, 2022
- Lilly Japan, DeNA Partner Up to Recruit Trial Participants with Collected Genetic Data
September 30, 2022
- US QIDP Status Awarded to Meropenem Combo Med for Carbapenem-Resistant Bacteria Infections: Kitasato/Sumitomo
September 30, 2022
- Chugai Files Perjeta/Herceptin Subcutaneous Combo in Japan
September 30, 2022
- Shionogi’s COVID Pill Hits Main Goal in PIII, Discussion on Regulatory Path to Follow
September 29, 2022
- Yakult Honsha Pulls NDA for Blood Cancer Med Duvelisib in Japan
September 29, 2022
- Taisho Files Autoinjector Version of RA Med Nanozora in Japan
September 29, 2022
- Maruishi/Kissei’s Pruritus Med Difelikefalin Filed in Japan
September 29, 2022
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…